Quality of life after use of the patient activated atrial defibrillator

International Journal of Clinical Practice

Volumn 57, Issue 1, 2003, Pages 30-35

  Spurrell, Philip ^b   Mitchell, A ^b   Kamalvand, K ^a   Sulke, N ^b  

^a WILLIAM HARVEY HOSPITAL   (United Kingdom)

^b EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; FLECAINIDE; SEDATIVE AGENT; SOTALOL;

ADULT; AGED; ANXIETY; CLINICAL ARTICLE; CONTROLLED STUDY; DEFIBRILLATION; DEFIBRILLATOR; DEPRESSION; DISEASE SEVERITY; DRUG SELF ADMINISTRATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; IMPLANTATION; LONG TERM CARE; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; REVIEW; SCORING SYSTEM; SINUS RHYTHM; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ATRIAL FIBRILLATION; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SELF CARE; TREATMENT OUTCOME;

EID: 12244292701     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-1022.
2. Furberg CD, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
4. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.
5. Lemery R, Brugada P, Cheriex E, Wellens HJ. Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation. Am J Cardiol 1987; 60: 1406-1408.
6. Jenkins LS, Bubien RS. Quality of life in patients with atrial fibrillation. Cardiol Clin 1996; 14: 597-606.
7. Luderitz B, Jung W. Quality of life in patients with atrial fibrillation. Arch Intern Med 2000; 160: 1749-1757.
8. Crijns HJ, Van Gelder IC, Van Gilst WH et al. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335-341.
9. Gosselink AT, Crijns HJ, Van Gelder IC et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289-3293.
10. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-263.
11. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
12. Gold MR, Sulke AN, Schwartzman D et al. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol 2001; 12: 1247-1253.
13. Murgatroyd FD, Slade AK, Sopher SM et al. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol 1995; 25: 1347-1353.
14. Ammer R, Alt E, Ayers G et al. Pain threshold for low energy intracardiac cardioversion of atrial fibrillation with low or no sedation. Pacing Clin Electrophysiol 1997; 20: 230-236. [Erratum in Pacing Clin Electrophysiol 1997; 20(4 Pt 1): viii].
15. Lok NS, Lau CP, Tse HF, Ayers GM. Clinical shock tolerability and effect of different right atrial electrode locations on efficacy of low energy human transvenous atrial defibrillation using an implantable lead system. J Am Coll Cardiol 1997; 30: 1324-1330.
16. Herrmann C, von zur MF, Schaumann A et al. Standardized assessment of psychological well-being and quality-of-life in patients with implanted defibrillators. Pacing Clin Electrophysiol 1997; 20: 95-103.
17. Burgess ES, Quigley JF, Moran G et al. Predictors of psychosocial adjustment in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1997; 20: 1790-1795.
18. Keren R, Aarons D, Veltri EP. Anxiety and depression in patients with life-threatening ventricular arrhythmias: impact of the implantable cardioverter-defibrillator. Pacing Clin Electrophysiol 1991; 14: 181-187.
19. Fitzpatrick AP, Kourouyan HD, Siu A et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pace-maker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131: 499-507.
20. Lonnerholm S, Blomstrom P, Nilsson L et al. Effects of the maze operation on health-related quality of life in patients with atrial fibrillation. Circulation 2000; 101: 2607-2611.
21. Spurrell P, Mitchell AR, Kamalvand K et al. The impact of atrial defibrillators on the natural history of persistent atrial fibrillation: does sinus rhythm beget more sinus rhythm? J Am Coll Cardiol 2001; 37: 95A. Abs.